Francesca J Torriani

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment
    Edward R Cachay
    Department of Medicine, University of California at San Diego, 200 West Arbor Drive, San Diego, California 92103, USA
    AIDS Res Ther 8:29. 2011
  2. ncbi Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s
    Francesca J Torriani
    Infection Prevention and Clinical Epidemiology Unit, University of California San Diego, 200 West Arbor Drive, MC 8951, San Diego, California 92103, USA
    J Am Coll Cardiol 52:569-76. 2008
  3. ncbi Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection
    Francesca J Torriani
    Department of Medicine, Division of Infectious Diseases, University of California, San Diego, California 92103, USA
    J Infect Dis 188:1498-507. 2003
  4. ncbi Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
    Francesca J Torriani
    Department of Medicine, Division of Infectious Diseases, University of California, San Diego, Antiviral Research Center, CA 92103, USA
    N Engl J Med 351:438-50. 2004
  5. ncbi Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection
    Gregory J Dore
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    AIDS 21:1555-9. 2007
  6. ncbi Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis
    Rachel D Schrier
    Division of Infectious Diseases, Department of Pathology, University of California San Diego, UCSD Medical Center, MC 8416, 200 W Arbor Drive, San Diego, CA 92103 8416, USA
    Retina 26:165-9. 2006
  7. ncbi Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection
    Milos Opravil
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 47:36-49. 2008
  8. ncbi Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection
    John Hornberger
    The SPHERE Institute Acumen, LLC, Burlingame, CA 94010, USA
    J Clin Virol 36:283-91. 2006
  9. ncbi Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, , Germany
    AIDS 18:F21-5. 2004
  10. ncbi Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections
    Francesca J Torriani
    ACP J Club 142:A12; author reply A13. 2005

Detail Information

Publications20

  1. ncbi Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment
    Edward R Cachay
    Department of Medicine, University of California at San Diego, 200 West Arbor Drive, San Diego, California 92103, USA
    AIDS Res Ther 8:29. 2011
    ..abstract:..
  2. ncbi Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s
    Francesca J Torriani
    Infection Prevention and Clinical Epidemiology Unit, University of California San Diego, 200 West Arbor Drive, MC 8951, San Diego, California 92103, USA
    J Am Coll Cardiol 52:569-76. 2008
    ..This study evaluated the effects of 3 class-sparing antiretroviral therapy (ART) regimens on endothelial function in human immunodeficiency virus (HIV)-infected subjects participating in a randomized trial...
  3. ncbi Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection
    Francesca J Torriani
    Department of Medicine, Division of Infectious Diseases, University of California, San Diego, California 92103, USA
    J Infect Dis 188:1498-507. 2003
    ..Although the early viral kinetics of coinfected subjects treated with PEG-IFN or IFN differ from those of singly infected subjects, the treatment response seems unaffected...
  4. ncbi Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
    Francesca J Torriani
    Department of Medicine, Division of Infectious Diseases, University of California, San Diego, Antiviral Research Center, CA 92103, USA
    N Engl J Med 351:438-50. 2004
    ....
  5. ncbi Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection
    Gregory J Dore
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    AIDS 21:1555-9. 2007
    ..To identify baseline characteristics predictive of a sustained virological response (SVR) in patients with HIV-hepatitis C virus (HCV) co-infection treated with interferon-based therapy...
  6. ncbi Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis
    Rachel D Schrier
    Division of Infectious Diseases, Department of Pathology, University of California San Diego, UCSD Medical Center, MC 8416, 200 W Arbor Drive, San Diego, CA 92103 8416, USA
    Retina 26:165-9. 2006
    ....
  7. ncbi Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection
    Milos Opravil
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 47:36-49. 2008
    ..The impact of baseline CD4 status on hepatitis C virus (HCV) treatment response among patients with HIV/HCV coinfection was investigated using data from a randomized study of peginterferon alfa-2a (40KD) + ribavirin (Peg-IFN/RBV)...
  8. ncbi Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection
    John Hornberger
    The SPHERE Institute Acumen, LLC, Burlingame, CA 94010, USA
    J Clin Virol 36:283-91. 2006
    ..The cost-effectiveness of treating these patients with peginterferon alfa-2a/ribavirin has yet to be explored from a US societal perspective...
  9. ncbi Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, , Germany
    AIDS 18:F21-5. 2004
    ..Treatment with antiretrovirals such as didanosine may increase the risk further...
  10. ncbi Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections
    Francesca J Torriani
    ACP J Club 142:A12; author reply A13. 2005
  11. ncbi Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure
    Judith S Currier
    Center for Clinical AIDS Research and Education, Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095, USA
    AIDS 19:927-33. 2005
    ..The impact of HIV infection and exposure to antiretroviral therapy on the development of subclinical atherosclerosis is incompletely understood...
  12. ncbi A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis
    Jacob Lalezari
    Quest Clinical Research, San Francisco, California 94115, USA
    J Acquir Immune Defic Syndr 30:392-400. 2002
    ..Other than a higher than expected frequency of oral candidiasis (17%), no clinical toxicities or laboratory abnormalities occurred during treatment with valganciclovir that have not been observed during treatment with ganciclovir...
  13. ncbi Cardiovascular effects of antiretroviral therapy and noninvasive assessments of cardiovascular disease in HIV infection
    Bruno R Cotter
    Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, CA 92103 8411, USA
    Cardiovasc Toxicol 4:281-6. 2004
    ..Multicenter, randomized trials using either technique may provide more information about whether HIV infection alone, long-term HAART use, or both may increase the risks of or accelerate coronary disease in HIV-infected patients...
  14. ncbi A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team
    Judith A Aberg
    Department of Medicine, Division of Infectious Disease, University of California San Francisco, San Francisco, CA, USA
    J Infect Dis 187:1046-52. 2003
    ..44/100 person-years (95% confidence interval, 0.04-8.01). Withdrawal of anti-MAC therapy appears to be safe in patients who have been treated with a macrolide-based regimen for at least 1 year and have an immunologic response on HAART...
  15. ncbi Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults
    Judith S Currier
    Center for Clinical AIDS Research and Education, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA
    AIDS 21:1137-45. 2007
    ..To compare the rate of change in intima-media thickness (IMT) of the carotid artery among uninfected subjects and HIV-infected subjects receiving or not receiving protease inhibitor (PI) regimens over a 144 week period...
  16. ncbi Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
    Richard K Sterling
    Section of Hepatology, Virginia Commonwealth University Health System, Richmond, VA 23298 0341, USA
    Hepatology 43:1317-25. 2006
    ..In conclusion, noninvasive tests can accurately predict hepatic fibrosis and may reduce the need for liver biopsy in the majority of HIV/HCV-coinfected patients...
  17. ncbi Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults
    Wm Christopher Mathews
    Department of Medicine, University of California, San Diego, Owen Clinic, UCSD Medical Center, San Diego, CA 92103, USA
    J Acquir Immune Defic Syndr 40:155-60. 2005
    ..This study's purpose was to estimate trends in the incidence of and risk factors for clinically significant MRSA (CS-MRSA) infection in a cohort of HIV-infected adults...
  18. ncbi Long-term results of treatment of macular complications in eyes with immune recovery uveitis using a graded treatment approach
    Mohamed H El-Bradey
    Shiley Eye Center, San Diego, CA 92093-0946, USA
    Retina 24:376-82. 2004
    ..Eyes with immune recovery uveitis that develop epiretinal membrane undergo some visual improvement after removal of the membrane. The macular edema of immune recovery uveitis is resistant to corticosteroid treatment...
  19. ncbi A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087
    Judith A Aberg
    AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 21:757-67. 2005
    ..Combination therapy with fenofibrate and pravastatin for HIV-related dyslipidemia provides substantial improvements in lipid parameters and appears safe, but is unlikely to achieve all NCEP targets for lipid levels...
  20. ncbi Response to: 'carotid intima-media thickness: assessment of sub-clinical atherosclerosis in HIV-infected patients'
    Judith S Currier
    AIDS 20:311. 2006